Table 2. Distribution of ART regimens among 58 HIV + kidney transplant recipients.
| ART regimen | Pre-transplant | Post-transplant † | Post-transplant
(12 months) |
|---|---|---|---|
| n (%) | n (%) * | n (%) º | |
| Single drug class combination | |||
| NRTI | 1 (2) | 1 (2) | 1 (2) |
| Two drug class combination | |||
| NRTI + PI | 30 (52) | 23 (40) | 11 (27) |
| NRTI + INSTI | 2 (3) | 12 (21) | 8 (20) |
| NRTI + NNRTI | 15 (26) | 9 (16) | 7 (17) |
| PI + INSTI | 4 (7) | 2 (3) | 2 (5) |
| NNRTI + INSTI | 1 (2) | 1 (2) | 0 |
| NNRTI + PI | 0 | 0 | 1 (2) |
| Three drug class combination | |||
| NRTI + PI + INSTI | 2 (3) | 6 (10) | 4 (10) |
| NRTI + PI + NNRTI | 2 (3) | 1 (2) | 0 |
| NRTI + INSTI + NNRTI | 1 (2) | 2 (3) | 4 (10) |
| NNRTI + INSTI + PI | 0 | 1 (2) | 2 (5) |
| Four drug combination | |||
| NRTI + INSTI + NNRTI + PI | 0 | 0 | 1 (2) |
ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, nonnucleoside reverse transcriptase inhibitors; PI, protease inhibitors.
†Refers to the ART regimen the patient was discharged home with after the initial transplant hospitalization.
ºData only available for 41 patients (due to death, loss of follow up, or insufficient documentation in medical record).
*Individual percentage values are rounded and might not total 100%.